AGENUS INC Operating Lease, Liability, Current
AGENUS INC (AGEN) had Operating Lease, Liability, Current of $1.10 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Leases
us-gaap:OperatingLeaseLiabilityCurrent · last filed 2026-08-07
- 2026-06-30: Operating Lease, Liability, Current $1.10M.
- 2026-03-31: Operating Lease, Liability, Current $1.05M.
- 2025-12-31: Operating Lease, Liability, Current $1.03M.
- 2025-09-30: Operating Lease, Liability, Current $1.11M.
| Period end | Operating Lease, Liability, Current |
|---|---|
| 2026-06-30 | $1.10M 10-Q · filed 2026-08-07 |
| 2026-03-31 | $1.05M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $1.03M 10-Q · filed 2026-08-07 |
| 2025-09-30 | $1.11M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $2.50M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $2.52M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $2.45M 10-K · filed 2026-03-16 |
| 2024-09-30 | $2.43M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $2.30M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $2.81M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $2.59M 10-K · filed 2025-03-17 |
| 2023-09-30 | $2.56M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $1.91M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $1.97M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $1.94M 10-K · filed 2024-03-14 |
| 2022-09-30 | $1.90M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $1.92M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $2.71M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $2.63M 10-K · filed 2023-03-16 |
| 2021-09-30 | $2.37M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $2.26M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $2.06M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $1.95M 10-K · filed 2022-03-01 |
| 2020-09-30 | $1.81M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $1.65M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $1.51M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $1.35M 10-K · filed 2021-03-16 |
| 2019-09-30 | $1.31M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $1.24M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $1.48M 10-Q · filed 2019-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |